Thursday, June 5, 2008

Avon Weighing Systems Limited IPO




Incorporated in 1999, Avon Weighing Systems Limited engaged in the business of selling weighing systems in India. Avon is classified as small scale industry. Avon is the authorized dealer and one of the distributors of A&D and Tanita’s weighing systems in India.

A&D is the third largest manufacturer of weighing systems in the world and they manufactures Analytical balances, Precision industrial balances, Moisture meters, Laboratory balances, Jewellery scales, Table top balances, Platform scales, Compact scales, Load cells, Weighing indicators and Viscosity meter etc. TANITA Corporation is one of the largest manufacturers for personal weighing scales, Mechanical/Digital bathroom & body fat monitor/scales, digital baby scale, professional fitness products - body composition analyzers/scales, etc.

Currently, they have manufacturing plant in Baddi (H.P.) where Avon manufactures the compact scales, platform scales, weighbridge & Tablet Calculation Systems- Auto Feeders with SQC software. They are mainly focusing into the industries like jewellery, Fitness centers, Hospitals, Clinics, Hotels & Shopping Malls.

Avon's clients are:

  1. Sports Fuel
  2. Larsen & Toubro Limited
  3. Pantaloon Retail (India) Ltd
  4. Rusan Pharma Ltd
  5. Glenmark Pharmaceuticals Ltd
  6. Godrej Industries Ltd
  7. Reliance Life Sciences Pvt Ltd, etc.

Objects of the Issue:

    The objects of the Issue are to achieve the benefits of listing on the Stock Exchanges & to raise capital to:
  1. Setting-up a full fledged manufacturing facility for indigenous manufacture of a particular range of weighing systems;
  2. Setting-up furniture & fixtures at factory, corporate office & showrooms;
  3. Setting-up computers and software and SAP systems;
  4. Contingency Provision;
  5. To meet the working capital requirement;
  6. To meet expenses of the Issue in order to achieve the benefits of listing on the Stock Exchanges;
  7. General corporate purposes.

Avon Weighing Systems Ltd IPO Information

»» Public Issue Open: June 09, 2008 to June 12, 2008
»» Public Issue Type: Fixed price
»» Public Issue Size: 98,36,400 Equity Shares of Rs. 10/-
»» Face Value: Rs. 10/-
»» Public Issue Price: Rs 10/-
»» Maximum Subscription Amount for Retail Investor: Rs 100,000/-
»» Listing: BSE
»» Lead Manager: Keynote Corporate Services Ltd
»» Registrar: Datamatics Financial Services Ltd (Ph: +91-22-66712151 Email: dnyanesh_gharote@vsnl.com)

Bafna Pharmaceuticals Limited IPO





Incorporated in 1995, Bafna Pharmaceuticals Limited is engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The Company manufactures 126 formulations under various therapeutic segments, such as anti-infective, cholesterol lowering agents, analgesic and antipyretic, antihelmintics, appetite stimulants, cough and cold preparations, antiulcerants anti diabetic, and vitamins.

In 2006, Bafna has set up an 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. The unit has been WHO GMP certified and also ISO 9000 certified. The products manufactured in this factory caters to the markets of Srilanka, Ghana and Ukraine. Bafna was involved in the execution of contracts for the generic division of M/s. Croslands from the period 1994 to 2001. Bafna was awarded the WHO GMP certification during the year 1995. Presently around 57 products of the company are registered in Srilanka, 4 products in Ukraine, 1 product in Ghana. The company received the Best Supplier award from the Srilankan Government during 2005.

The present installed capacity of different categories of products manufactured by Bafna are:

Products Installed capacity on one shift basis Madhavaram unit Installed capacity on one shift basis Madhavaram EOU unit Installed capacity on one shift basis Grantlyon unit
Tablets 8344.30 lacs 6973.20 lacs 7195.00 lacs
Capsules 2737.70 lacs 2462.40 lacs 2250.00 lacs
Oral syrups 417600 Litres - -

Objects of the Issue:

    The objects of the Issue are to achieve the benefits of listing on the Stock Exchanges & to raise capital:
  1. To undertake Brand Building exercise in domestic & international markets;
  2. To part finance the cost of obtaining MHRA approval for Grantlyon unit;
  3. To set up a Research & Development unit at Grantlyon;
  4. To repay high cost debt;
  5. To meet the working capital requirement;
  6. To meet expenses of the Issue in order to achieve the benefits of listing on the Stock Exchanges;
  7. General corporate purposes.

Bafna Pharmaceuticals Ltd IPO Information

»» Public Issue Open: May 27, 2008 to May 30, 2008
»» Public Issue Type: Fixed price
»» Public Issue Size: 64,00,000 Equity Shares of Rs. 10/-
»» Face Value: Rs. 10/-
»» Public Issue Price: Rs 40/-
»» Maximum Subscription Amount for Retail Investor: Rs 100,000/-
»» Listing: BSE
»» Lead Manager: Keynote Corporate Services Ltd, Ashika Capital Ltd
»» Registrar: Cameo Corporate Services Ltd (Ph: +91-44-28460390 Email: cameo@cameoindia.com)